LG100754 UVI 2112,99.0%
产品编号:Bellancom-108523| CAS NO:180713-37-5| 分子式:C26H36O3| 分子量:396.56
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
LG100754 UVI 2112
产品介绍 | LG100754 (UVI 2112) 是一种 RXR 二聚体 的调节剂。LG100754 作为同源二聚体 RXR:RXR 的拮抗剂,但作为异源二聚体 RXR: PPARα 和 RXR: PPARγ 的激动剂。LG100754 是一种通过 RXR 起作用的胰岛素增敏剂。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR. | ||||||||||||||||
体外研究 |
LG100754 is a selective activator of endogenous RXR heterodimers. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (252.17 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在 西域 网站选购。
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |